Sam Williams

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

J Affect Disord October 10, 2025 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. correction

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

DOI: 10.1016/j.jad.2025.120352 (opens in new tab) Psilocybin Treatment-resistant depression Psychedelic experience Unique experience +7

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Journal of Affective Disorders March 1, 2025 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 35 citations

To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with...

DOI: 10.1016/j.jad.2024.12.061 (opens in new tab) Full text (opens in new tab) Magic mushrooms Treatment-resistant depression Psychedelics psilocybin Hallucinogens +8

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology September 1, 2023 Guy M. Goodwin, Megan Croal, David Feifel et al. 166 citations

Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility of ongoing antidepressant drugs altering the psychedelic effect. This phase II, exploratory, international, fixed-dose, open-label study explored the safety,...

DOI: 10.1038/s41386-023-01648-7 (opens in new tab) Full text (opens in new tab) Depression Psychedelics Mental health Psilocybin therapy +1

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Journal of Affective Disorders February 3, 2023 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 168 citations

Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.

DOI: 10.1016/j.jad.2023.01.108 (opens in new tab) Anxiety Psilocybin Antidepressant Patient-reported outcomes +5

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation

Journal of Psychopharmacology 2022 James Rucker, Lindsey Marwood, Riikka-Liisa Johanna Ajantaival et al. 101 citations

Background: Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not been widely or systematically studied. Aim: The aim of this study was to explore the safety of simultaneous administration of psilocybin to healthy participants in the largest randomised...

DOI: 10.1177/02698811211064720 (opens in new tab) Psilocybin Placebo Adverse effect Randomized controlled trial +2